Phase 4 N=600 Premature Discontinuation of Contraceptive Implants
Contraception Behavior
Primary: Number of Participants With Implant Continuation — 219; 225 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,919 Evaluation of Participant Responses to Educational Counseling About Different Combined Hormonal Contraceptive Choices (P06557)
Contraception
Primary: Number of Participants Choosing Each Hormonal Contraceptive Method Before and After Counseling — 1207; 1199; 60; 131 Participants — p=0.705
N/A N=321 A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods
Contraception
Primary: Continuation Rates — 82; 78; 83 participants
N/A N=138 Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II
Contraceptive Usage · Opioid Dependence
Primary: Percentage of Participants With Verified Prescription Contraceptive Use at the 6-month Assessment — 5; 14; 23 Participants — p=<.001
N/A N=64 Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Primary: Follicle-stimulating Hormone — 5.01; 5.86; 6.38 milli international units per milliliter — p=0.88
Phase 2 N=32 Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study
Uterine Hemorrhage · Contraception
Primary: Cessation of Vaginal Bleeding — 37.5; 87.5 percentage of participants
Early Phase 1 N=40 Ovarian Function With ENG Implant and UPA Use
Contraception
Primary: Number of Participants With Ovulation With Implant-alone — 7; 0 Participants
Phase 4 N=88 'Levonorgestrel IUD Insertion After D&E Procedure
Contraceptive Usage
Primary: The Primary Outcome is LNG-IUD Usage Six Months Following Enrollment. — 85.2; 62.9 percentage of participants — p=0.05
N/A N=57 Copper T380 IUD Versus Oral Levonorgestrel for Emergency Contraception vs. Plan B for Emergency Contraception
Pregnancy
Primary: Use of an Effective Method of Contraception at 6 Months After Requesting Emergency Contraception — 9; 13 participants
N/A N=293 Same Day Oral EC and Implant Initiation
Contraception
Primary: Pregnancy Rate at One-month — 1.96 percentage of participants
Phase 4 N=69 Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant
Complications; Contraceptive · Female Lactation
Primary: Time to Lactogenesis Stage II — 64.3; 65.2 hours — p=<0.05
N/A N=38 Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression
Menopausal and Other Perimenopausal Disorders
Primary: Hot Flashes — 10.3; 7.944 scores on a scale
Phase 4 N=109 Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users
Bleeding · Implants · Breakthrough Bleeding
Primary: Total Number of Consecutive Bleeding-free Days in First 30 Days From Day 1 of First Treatment (TX1) — 18.5; 8.7 days
Phase 4 N=24 Rifampin and the Contraceptive Implant
Contraception · Tuberculosis
Primary: Serum Etonogestrel Concentrations — 164.0; 47.8 pg/mL
N/A N=253 Computerized Contraceptive Decision Aid
Contraception · Decision Making · Satisfaction
Primary: Decisional Conflict Scale Score — 15; 10; 0; 0 score on a scale
Phase 4 N=59 Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk
HIV · Contraception
Primary: Percent of HIV Target Immune Cells Within Female Genital Mucosa and Blood — 26.6; 22.8; 16.9; 22.4 percentage of HIV target immune cells
N/A N=1,008 Innovative Model of Patient-Centered ConTraception
Contraception · Unintended Pregnancy
Primary: Unintended Pregnancy — 46; 25 Participants
Phase 2 N=286 Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception
Contraception
Primary: The Primary Outcome Measure is Effectiveness as Calculated by the Pearl Index — 0.53; 1.41; 0.00 Pearl Index
N/A N=786 Patient-Centered Support for Contraceptive Decision-Making
Contraception · Contraceptive Behavior
Primary: Contraceptive Continuation — 201; 174; 154; 118 Participants — p=0.46
N/A N=246 Contraceptive Counseling Following an Abortion
Post Abortion Care
Primary: Contraceptive Acceptability and Use of Contraceptives During the 6-month Follow-up — 121; 86 participants
Phase 3 N=567 LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study
Contraception
Primary: Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF) — 82.1; 81.9 Percentage of participants
Phase 3 N=65 Intervention to End Recurrent Unscheduled Bleeding Trial
Contraception · Bleeding
Primary: Number of Bleeding/Spotting Days With Use of Ulipristal Acetate as Measured by Daily Bleeding Diaries — 7; 12 days — p=0.002
N/A N=207 RCT: Can a Single Counseling Phone Call Improve Contraception After an Abortion?
Contraception
Primary: Number of Participants Using an Effective Contraceptive Method 6 Weeks After Abortion — 55; 55 Participants
Phase 4 N=96 Postpartum Etonogestrel Implant for Adolescents
Adolescence · Contraception · Postpartum
Primary: Continuation at 1 Year — 21; 30 participants
Phase 4 N=36 Oral Contraceptives in the Metabolic Syndrome
Metabolic Syndrome X · Insulin Resistance · Obesity
Primary: Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women — 4.36; 6.62; 3.82; 8.23 mIU/L
Phase 4 N=894 Long-Acting Reversible Contraception
Contraception
Primary: Contraceptive Method Discontinuation — 300; 62; 142 Participants
N/A N=298 Trial of Immediate Versus Delayed Initiation of Transdermal Hormonal Contraception After Therapeutic Abortion
Abortion
Primary: Number of Participants Who Use Patch After Abortion, by Study Arm — 36; 42 Participants
N/A N=100 The Impact of Contraception on Postpartum Weight Loss
Weight
Primary: Weight — 3.2; 6.8; 7.0 percent weight lost — p=<0.05
Phase 3 N=1,384 AMP002 Phase III Contraceptive Study
Contraception
Primary: Number of Subjects With Pregnancy Outcomes to Measure Contraceptive Efficacy — 100 Participants
N/A N=197 Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial
Breast Feeding · Contraception
Primary: Number of Participants Who Continued to Breastfeed at 6 Months — 15; 14; 8; 9 participants